Browse > Article

CpG DNA for Treatment of Allergic Diseases  

Choi, Sung Min (Department of Pediatrics, Dongguk University College of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.48, no.3, 2005 , pp. 251-259 More about this Journal
Abstract
Atopy is a highly prevalent and serious health problem. The prevalence and severity of asthma and allergic diseases have increased over recent decades, particularly in industrialized nations. Early life infections may protect against the development of atopy and allergic diseases like asthma. The inverse relationship between the incidence of atopy and childhood infections has led to the 'hygiene hypothesis', which suggests that diminished exposure to childhood infections in modern society has led to decreased Th1-type responses. Th1 and Th2 responses are counter-regulatory. Reduced Th1 may lead to enhanced Th2-type inflammation, which is important in promoting asthma and allergic disease via up-regulation of IL-4, IL-5, and IL-13. It is now widely accepted that altered regulation of Th2 responses(and possibly the balance between Th1 and Th2 responses) is an important factor in the development of atopy. CpG DNA represent a novel class of drugs with substantial immunomodulatory properties. CpG DNA contain unmethylated motifs centered on the CpG dinucleotides, like bacterial DNA. These CpG DNA promote Th1 and regulatory type immune responses and suppress Th2 responses. In murine studies, CpG DNA are effective in prevention and treatment of asthma and allergic diseases. CpG DNA are just beginning to be tested in human asthma. While its precise mechanisms continue to be fully studied, CpG DNA offers considerable promise as a novel treatment for atopic inflammation. It may prove to be an important disease modifying therapy, or even curative therapeutic agent for asthma and allergic diseases.
Keywords
Allergic diseases; Asthma; CpG DNA; Immunomodulation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164:944-53
2 Ikeda RK, Miller M, Nayar J, Walker L, Cho JY, McElwain K, et al. Accumulation of peribronchial mast cells in a mouse model of OVA allergen induced chronic airway inflammation : modulation by immunostimulatory DNA sequences. J Immunol 2003;171:4860-7
3 Hwang HW, Kim SJ, Kim WD, Cho SM, Lee DS, Choi SM. Effect of CpG oligodeoxynucleotides on airways of mice with established airways inflammation. J Korean Pediar Soc 2002;45:875-83
4 Choi SM. CpG ODNs for treatment of bronchial asthma. J Korean Pediatr Allergy Respir Dis 2003;13:207-15
5 Jakob T,Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides : A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998;161:3042-9
6 Wild JS, Sur S. CpG oligonucleotide modulation of allergic inflammation. Allergy 2001;56:365-76   DOI   ScienceOn
7 Serebrisky D, Teper DD, Huang CK, Lee SY, Zhang TF, Schofield BH, et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000;165:5906-12
8 Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2149-53   DOI   ScienceOn
9 Mok JS, Choi SM. Modulation of eosinophilia and cytokines of bronchoalveolar larvage fluid(BALF) by CpG oligodeoxynucleotides(ODN) in a mouse model of established airway inflammation. J Korean Pediatr Allergy Respir Dis 2002;12:93-104
10 Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161:7054-62
11 Jain VV, Kline JN. CpG DNA : immunomodulation and remodelling of the asthmatic airway. Expert Opin Biol Ther 2004;4:1533-40   DOI   ScienceOn
12 Kibe A, Inoue H, Fukuyama S, Machida K, Matsumoto K, Koto H, et al. Differential regulation by glucocorticoid of interleukin-13 induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. Am J Respir Crit Care Med 2003;167:50-6   DOI   ScienceOn
13 Akbari O, Stock P, DeKruyff RH, Umetsu DT. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol 2003;15:627-33   DOI   ScienceOn
14 Ramsey CD, Celedon JC. The hygiene hypothesis and asthma. Curr Opin Pulm Med 2005;11:14-20   DOI   PUBMED   ScienceOn
15 Ikeda RK, Nayar J, Cho JY, Miller M, Rodriguez M, Raz E, et al. Resolution of airway inflammation following ovalbumin inhalation : comparison of ISS DNA and corticosteroids. Am J Respir Cell Mol Biol 2003;28:655-63   DOI   ScienceOn
16 Shirota H, Sano K, Kikuchi T, Tamura G, Shirata K. Regulation of murine airway eosinophilia and Th2 cells by antigen conjugated CpG oligodeoxynucleotides as a novel antigen specific immunomodulator. J Immunol 2000;164:575-82
17 Norman PS. Immunotherapy : 1999-2004. J Allergy Clin Immunol 2004;113:1013-23
18 Hussain I, Kline JN. DNA, the immune system, and atopic disease. J Investig Dermatol Symp Proc 2004;9:23-28   DOI   ScienceOn
19 Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H, et al. Immune cell activation by bacterial CpG DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor associated factor(TRAF) 6. J Exp Med 2000;192:595-600.   DOI   ScienceOn